At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Controlled, Multi-Center Study on the Efficacy of a Sustained Release Progesterone Cerclage Cervical Pessary at Doses of 6.3 g or 7.7 g for the Prevention of Preterm Birth and a Maximum Duration of 20 Weeks.
In Brief
A Phase 2 clinical trial evaluating Progesterone Cervical Pessary 6.3 g, Progesterone 200 mg vaginal capsules, and 1 other intervention for Preterm Birth. Completed, enrolled 271 participants across 4 sites.
Detailed Summary
Assess the efficacy of 2 Cervical Pessaries containing 6.3 g and 7.7 g micronized progesterone for the prevention of preterm delivery, established through spontaneous birth before gestation weeks 32 (31 weeks and 6 days) and 34 (33 weeks and 6 days), when the pessary is inserted during weeks 16th and 24th and removed at 36 weeks and 6 days in pregnant women at high risk of premature birth.
Study Details
Timeline
Interventions
Progesterone Cervical Pessary low dose
Progesterone 200 mg vaginal capsules daily
Progesterone Cervical Pessary high dose